TASK DEFINITION: Given a sentence and an entity, the task is to select the authors sentiment towards the enity. Sentiments can be Positive, Neutral and Negative. Select Positive if the sentence expresses a positive view towards the given entity or praises its quality or skills. Select Neutral if the sentence expresses no clear view towards the entity or has equal amounts of positive and negative statements or expressing some fact/quote by someone else. Select Negative if the sentence expresses a negative view towards like harsh remarks, criticizing entities action/decision etc. Note that URLs in the text have been replaced with [Link].
PROBLEM: What is the sentiment of the following document towards the entity Hope Hicks ? Earlier this month  Hicks  was deeply involved in the White House's botched handling of domestic abuse allegations against a former top aide to the president. But a White House official insists  Hicks ' decision to resign wasn't related to either of those matters.

SOLUTION: Neutral

PROBLEM: What is the sentiment of the following document towards the entity Romualdo Pacheco ? (CNN)  Romualdo Pacheco  was not only the first Hispanic governor of California  the 19th century politician was also the state's only Hispanic governor to date. Not to be outdone by  himself    Pacheco  was also the first Hispanic member of the House with full voting rights.

SOLUTION: Positive

PROBLEM: What is the sentiment of the following document towards the entity David Mitchell ? Zhang: As you know  Novartis disputes the $200 million figure because not all of that money went directly to CAR-T for cancer or toward the specific therapy behind Kymriah.  Mitchell : We're going to send you a clip from a blog post by Francis Collins  the head of the National Institutes of Health  in which  he  explains the long history of NIH in building the foundational science for CAR-T. Here's our position: From 1993 until 2017  NIH invested more than $200 million in the overall science of CAR-T. Even the seminal paper that was published in August of 2011 by Dr. Carl June of the University of Pennsylvania was funded in part by the NIH. All of the makers—Novartis  Kite (which will become Gilead)  and Juno [other companies pursuing CAR-T cell therapy]—are standing on that foundational science. The taxpayers invested early when the risk was the greatest. Zhang: What do you think is a fair price for Kymriah? Mitchell: Well  we have run the numbers a variety of different ways. Now  the point is no one knows the real numbers except Novartis  so we go back to the statements in a Reuters article in 2015 where Kite’s chief financial officer said they thought the base price was $150 000 for treatment  and analysts at that time were saying [costs could be] up to $300 000. When we tried to model  we can’t get over $300 000. Zhang: Novartis did take two unusual steps when announcing the price of Kymriah. First  they pointed to a British analysis to say they actually thought Kymriah was worth $600 000 to $750 000 but they were going to price it lower at $475 000. And second  they said patients who don’t respond after 30 days to the treatment will not have to pay.

SOLUTION:
Positive